Boutique Venture Partners

Surge2surgery is an immunological model capable of predicting postoperative infections. The company combines a single-cell assessment of the immune system before surgery with clinical data using a proprietary machine-learning algorithm. By analyzing the millions of immune cells in a small amount of blood, the platform can mimic surgical trauma in a test tube before surgery.

miRecule, Inc. is a biotechnology company specializing in the development of microRNA-based therapeutics, with a focus on addressing challenges in cancer treatment and other diseases such as muscular dystrophy. Founded in 2016 and headquartered in Gaithersburg, Maryland, the company has created a drug discovery platform called DREAmiR. This platform leverages genomic and outcome data from thousands of patients to identify genetic changes linked to diseases. It combines genomic sequencing, expression, and prognostic data from cancer patients with high-throughput screening data to pinpoint microRNA candidates for replacement therapy. miRecule's approach aims to formulate these candidates into tumor-targeted nanoparticles, enabling oncologists to effectively target and eliminate drug-resistant cancer cells.

DocBot, Inc. is a technology company based in Irvine, California, that develops web-based applications for iOS and Android devices. The company's offerings include a clinical decision support system and cloud analytics, which aggregate patient information to assist physicians and specialists in delivering improved care. Additionally, DocBot has created an image analysis platform specifically designed to aid in the detection of colorectal cancer and gastrointestinal diseases. This platform integrates various data sources, including imaging systems and pathology requisitions, enabling healthcare providers to enhance patient outcomes while reducing cancer risk. Through its commitment to intuitive software design, DocBot aims to empower physicians in their clinical decision-making processes.

FluidAI Medical is focused on developing an innovative implantable biochip equipped with biosensors designed to detect post-operative complications, including internal bleeding, fluid leakage, and infections within the abdominal cavity. This advanced biosensor continuously collects data, identifying complications as they arise, and provides real-time notifications to both patients and healthcare providers. Specifically, the device aims to manage risks associated with surgeries by monitoring for anastomotic leakage, which involves gastrointestinal fluid leaking into the abdominal cavity. The biosensor is integrated into a catheter, where it resides within the abdominal cavity, while a monitoring unit remains external. When the biosensor detects changes indicative of a leak, it transmits alerts through the catheter to the external monitor. Data is continuously uploaded to the cloud for further analysis, ensuring timely alerts are sent to patients' smartphones, prompting them to seek medical attention, while offering detailed information to their doctors. Founded in 2014 and based in Kitchener, Canada, FluidAI Medical serves physicians, surgeons, hospitals, and patients with its groundbreaking technology.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, that specializes in developing novel drug conjugates for targeted bone therapy. Founded in 2013, the company utilizes a proprietary prodrug platform that selectively delivers therapeutics to bone, addressing challenging medical conditions such as osteoporosis and Duchenne muscular dystrophy. Its lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic designed to reverse bone loss by effectively targeting mesenchymal stem cells. This innovative approach enables the delivery of active pharmaceutical agents directly to the bone, minimizing systemic side effects often associated with high-dose treatments. Pre-clinical in-vivo models have validated the efficacy of Mesentech's technology, positioning the company to advance treatments for low-bone-density disorders and improve outcomes in bone healing and regeneration.

DocBot, Inc. is a technology company based in Irvine, California, that develops web-based applications for iOS and Android devices. The company's offerings include a clinical decision support system and cloud analytics, which aggregate patient information to assist physicians and specialists in delivering improved care. Additionally, DocBot has created an image analysis platform specifically designed to aid in the detection of colorectal cancer and gastrointestinal diseases. This platform integrates various data sources, including imaging systems and pathology requisitions, enabling healthcare providers to enhance patient outcomes while reducing cancer risk. Through its commitment to intuitive software design, DocBot aims to empower physicians in their clinical decision-making processes.

miRecule, Inc. is a biotechnology company specializing in the development of microRNA-based therapeutics, with a focus on addressing challenges in cancer treatment and other diseases such as muscular dystrophy. Founded in 2016 and headquartered in Gaithersburg, Maryland, the company has created a drug discovery platform called DREAmiR. This platform leverages genomic and outcome data from thousands of patients to identify genetic changes linked to diseases. It combines genomic sequencing, expression, and prognostic data from cancer patients with high-throughput screening data to pinpoint microRNA candidates for replacement therapy. miRecule's approach aims to formulate these candidates into tumor-targeted nanoparticles, enabling oncologists to effectively target and eliminate drug-resistant cancer cells.

Zeda is a medical device manufacturer that specializes in the integration of advanced technologies such as metal 3D printing and nanotechnology to create innovative healthcare solutions. The company is known for its PrinterPrezz GAIA™ Lumbar Interbody Fusion Device, among other products. Established in 2017 and located in Fremont, California, Zeda aims to accelerate the development and market introduction of new medical devices by merging the fields of medicine and manufacturing. By leveraging its expertise in 3D printing, orthopedics, and semiconductor technology, Zeda positions itself as a leader in the emerging field of Medifacturing™, striving to enhance both the efficiency and effectiveness of medical treatments.

FluidAI Medical is focused on developing an innovative implantable biochip equipped with biosensors designed to detect post-operative complications, including internal bleeding, fluid leakage, and infections within the abdominal cavity. This advanced biosensor continuously collects data, identifying complications as they arise, and provides real-time notifications to both patients and healthcare providers. Specifically, the device aims to manage risks associated with surgeries by monitoring for anastomotic leakage, which involves gastrointestinal fluid leaking into the abdominal cavity. The biosensor is integrated into a catheter, where it resides within the abdominal cavity, while a monitoring unit remains external. When the biosensor detects changes indicative of a leak, it transmits alerts through the catheter to the external monitor. Data is continuously uploaded to the cloud for further analysis, ensuring timely alerts are sent to patients' smartphones, prompting them to seek medical attention, while offering detailed information to their doctors. Founded in 2014 and based in Kitchener, Canada, FluidAI Medical serves physicians, surgeons, hospitals, and patients with its groundbreaking technology.

QMENTA is a cloud-based platform focused on medical image analysis and visualization, specifically aimed at enhancing the diagnosis and treatment of brain diseases. By enabling specialists such as neurologists, neurosurgeons, and neuroradiologists to upload and process medical images through a user-friendly interface, QMENTA facilitates advanced analyses and visualization without the need for software installation. The platform houses patented, AI-powered analytical algorithms alongside a marketplace of partnered algorithms, allowing for efficient data management and insights extraction from large-scale brain images. Additionally, it supports compliance with regulatory standards, ensuring the privacy and security of patient data. Researchers worldwide utilize QMENTA's scalable platform to advance their understanding and analysis of extensive image datasets, ultimately accelerating the development of new treatments for brain conditions.

Developer of a wearable device intended to prevent the progression of glaucoma and irreversible blindness. The company's technology utilizes a microfluidic-based smart contact lens and a smartphone app powered by AI (artificial intelligence) to monitor intraocular pressure (IOP), clinical trials have demonstrated a strong correlation with office-based standard-of-care devices, positioning the company as the first to offer an accurate and convenient method for monitoring the risk and progression of glaucoma, enabling patients to get an efficient and convenient way of monitoring IOP at home.

Frontier Bio Corporation is a biotechnology company based in Oakland, California, that specializes in the development and manufacturing of advanced bioprinting technologies. Founded in 2018, the company has created a unique bioprinter known as FLUX-1, which integrates traditional bioprinting methods with electro-hydrodynamic printing. This innovative approach allows for the precise printing of biological materials at the micro and nanoscale while preserving high cell viability. The FLUX-1 bioprinter is utilized for a range of applications, including the fabrication of tissues such as skin, cartilage, and bone, as well as for drug toxicity testing, tissue implants, drug screening, disease modeling, and the production of prosthetics. Frontier Bio's technology represents a significant advancement in the field of bioprinting, offering new possibilities for medical and research applications.

Zeda is a medical device manufacturer that specializes in the integration of advanced technologies such as metal 3D printing and nanotechnology to create innovative healthcare solutions. The company is known for its PrinterPrezz GAIA™ Lumbar Interbody Fusion Device, among other products. Established in 2017 and located in Fremont, California, Zeda aims to accelerate the development and market introduction of new medical devices by merging the fields of medicine and manufacturing. By leveraging its expertise in 3D printing, orthopedics, and semiconductor technology, Zeda positions itself as a leader in the emerging field of Medifacturing™, striving to enhance both the efficiency and effectiveness of medical treatments.